Compare TELA & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TELA | MIRA |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 43.7M |
| IPO Year | 2019 | 2023 |
| Metric | TELA | MIRA |
|---|---|---|
| Price | $0.92 | $0.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 209.8K | 131.9K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $80,275,000.00 | N/A |
| Revenue This Year | $10.23 | N/A |
| Revenue Next Year | $14.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.84 | N/A |
| 52 Week Low | $0.50 | $0.90 |
| 52 Week High | $2.19 | $2.45 |
| Indicator | TELA | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 37.49 |
| Support Level | $0.59 | $0.90 |
| Resistance Level | $1.24 | $1.24 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 28.79 | 12.95 |
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.